Loading…
Medicamen Biotech (MEDICAMEQ)₹279.55−0.50%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Medicamen Biotech reported sales of ₹47.72 Cr, up 11.3% from Jun 2025, and net profit of ₹1.84 Cr, up 15.7% year on year. For the year to Mar 2026, sales were ₹197 Cr and net profit ₹9.96 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43.40 | 46.32 | 47.16 | 42.92 | 44.55 | 44.99 | 29.52 | 42.89 | 47.01 | 46.73 | 60.49 | 47.72 |
| Expenses | 38.92 | 41.61 | 41.58 | 39.61 | 39.45 | 38.45 | 31.21 | 38.44 | 42.02 | 42.52 | 55.20 | 43.56 |
| Operating Profit | 4.64 | 4.89 | 5.74 | 3.44 | 5.30 | 6.70 | −1.60 | 4.60 | 5.15 | 4.37 | 5.42 | 4.32 |
| OPM % | 10.6% | 10.5% | 12.1% | 8.0% | 11.8% | 14.8% | −5.5% | 10.7% | 10.9% | 9.3% | 8.9% | 9.0% |
| Other Income | 0.54 | 0.82 | 0.56 | 0.58 | 0.30 | 0.13 | 5.22 | 0.46 | 0.36 | 0.52 | 1.73 | 0.85 |
| Interest | 0.92 | 0.66 | 1.90 | 0.72 | 1.05 | 0.77 | 0.66 | 1.16 | 1.00 | 0.98 | 0.39 | 0.84 |
| Depreciation | 1.81 | 1.79 | 1.76 | 1.76 | 2.60 | 2.20 | 0.47 | 1.79 | 1.85 | 1.84 | 1.74 | 1.78 |
| Profit before tax | 2.46 | 3.29 | 2.65 | 1.57 | 1.94 | 3.89 | 2.48 | 2.12 | 2.69 | 2.10 | 5.07 | 2.58 |
| Tax % | 39.6% | 38.1% | 22.8% | 48.7% | 53.8% | 24.7% | 25.2% | 24.8% | 21.2% | 22.2% | 12.0% | 28.4% |
| Net Profit | 1.46 | 2.02 | 2.03 | 0.79 | 0.90 | 2.91 | 1.86 | 1.59 | 2.11 | 1.63 | 4.43 | 1.84 |
| EPS (Rs) | 1.20 | 1.91 | 1.69 | 1.07 | 1.16 | 2.74 | 1.91 | 1.60 | 1.98 | 1.62 | 2.86 | 1.57 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 124 | 113 | 115 | 141 | 178 | 163 | 197 | 202 |
| Expenses | 105 | 106 | 93.03 | 91.03 | 117 | 156 | 148 | 178 | 183 |
| Operating Profit | 16.98 | 19.98 | 19.98 | 23.97 | 23.97 | 23.99 | 13.98 | 19.99 | 19.26 |
| OPM % | 14.0% | 16.0% | 17.0% | 21.0% | 17.0% | 13.0% | 9.0% | 10.0% | 9.5% |
| Other Income | 3.99 | 1.99 | 0.99 | 1.99 | 1.99 | 1.99 | 5.99 | 2.99 | 3.46 |
| Interest | 1.01 | 1.01 | 2.01 | 2.01 | 3.01 | 6.01 | 4.01 | 4.01 | 3.21 |
| Depreciation | 1.99 | 2.01 | 2.99 | 5.99 | 5.99 | 6.99 | 6.99 | 7.01 | 7.21 |
| Profit before tax | 17.99 | 18.01 | 16.01 | 17.99 | 16.98 | 12.99 | 9.99 | 12.01 | 12.44 |
| Tax % | 30.9% | 25.9% | 26.0% | 17.9% | 13.9% | 26.9% | 33.9% | 17.9% | — |
| Exceptional items | 0.00 | −0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 11.95 | 12.95 | 11.96 | 14.95 | 14.95 | 8.97 | 6.98 | 9.96 | 10.01 |
| EPS (Rs) | 10.29 | 10.89 | 9.94 | 12.21 | 11.75 | 8.61 | 5.60 | 7.12 | 8.03 |
| Dividend payout % | 10.0% | 5.0% | 10.0% | 8.0% | 9.0% | 12.0% | 18.0% | 14.0% | — |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12.01 | 12.01 | 12.02 | 12.02 | 13.01 | 13.02 | 13.02 | 14.02 |
| Reserves | 74.69 | 109 | 121 | 134 | 180 | 193 | 200 | 261 |
| Borrowings | 11.99 | 10.99 | 18.98 | 26.00 | 25.98 | 31.01 | 33.97 | 47.98 |
| Other Liabilities | 38.17 | 49.23 | 42.21 | 53.25 | 59.29 | 56.27 | 50.24 | 49.24 |
| Total Liabilities | 137 | 181 | 194 | 226 | 279 | 295 | 297 | 371 |
| Fixed Assets | 24.05 | 34.03 | 90.16 | 92.21 | 93.12 | 92.19 | 87.20 | 85.18 |
| CWIP | 15.02 | 40.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 96.79 | 107 | 104 | 133 | 186 | 203 | 210 | 286 |
| Inventories | 15.01 | 17.03 | 5.01 | 27.05 | 45.09 | 59.09 | 62.08 | 70.05 |
| Trade receivables | 43.11 | 50.15 | 53.15 | 63.20 | 65.24 | 55.14 | 69.25 | 82.21 |
| Cash & equivalents | 9.03 | 3.01 | 4.02 | 4.01 | 21.06 | 15.05 | 4.01 | 31.11 |
| Total Assets | 137 | 181 | 194 | 226 | 279 | 295 | 297 | 371 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 3.99 | 12.98 | 12.98 | 3.99 | −5.99 | −6.99 | −7.98 | −32.95 |
| Cash from investing activity | −14.95 | −36.91 | −17.97 | −7.98 | −5.98 | −5.99 | −0.99 | −2.99 |
| Cash from financing activity | −3.99 | 18.96 | 5.99 | 3.99 | 28.96 | 5.99 | −0.99 | 63.91 |
| Net cash flow | −13.97 | −4.99 | 0.99 | 0.00 | 16.97 | −5.99 | −10.98 | 27.97 |
| Capex | 15.67 | 37.57 | 17.94 | 8.60 | 6.59 | 6.28 | 2.18 | 4.77 |
| Free cash flow | −10.99 | −24.99 | −5.01 | −3.99 | −12.99 | −13.01 | −9.99 | −37.97 |
| CFO / OP % | 48.0% | 88.0% | 87.9% | 29.9% | −13.1% | −16.0% | −47.1% | −159.1% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 129 | 145 | 170 | 200 | 169 | 112 | 155 | 151 |
| Inventory days | 68 | 79 | 28 | 189 | 229 | 235 | 269 | 252 |
| Days payable | 134 | 173 | 169 | 302 | 241 | 154 | 184 | 144 |
| Cash conversion cycle | 63 | 52 | 29 | 87 | 157 | 194 | 240 | 260 |
| Working capital days | 117 | 131 | 127 | 148 | 157 | 124 | 187 | 194 |
| ROCE % | — | 16.0% | 13.0% | 12.0% | 10.0% | 8.0% | 6.0% | 5.0% |
For the Jun 2026 quarter, Medicamen Biotech reported sales of ₹47.72 Cr, up 11.3% year on year and net profit of ₹1.84 Cr, up 15.7% year on year. The operating margin was 9.0%.
Medicamen Biotech's sales for the year to Mar 2026 were ₹197 Cr; over the last twelve months they were ₹202 Cr.
Net profit for the year to Mar 2026 was ₹9.96 Cr, and ₹10.01 Cr over the last twelve months. Earnings per share over the same trailing period were ₹8.03.
Medicamen Biotech reported borrowings of ₹47.98 Cr at Mar 2026, against cash and equivalents of ₹31.11 Cr.
Cash from operations was −₹32.95 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹37.97 Cr.